GRIN2B and schizophrenia: Selective antagonists to both GluN2A (NVP-AAM077) and GluN2B (Ro25–6981) have shown antidepressant-like effects without psychotomimetic-like activities preclinically [124,133,145]; however, combination administration of these two agents was sufficient to generate schizophrenia-like stereotypical behaviour [145].